Literature DB >> 32484794

Rapamycin and dexamethasone during pregnancy prevent tuberous sclerosis complex-associated cystic kidney disease.

Morris Nechama1, Yaniv Makayes1, Elad Resnick1, Karen Meir2, Oded Volovelsky1.   

Abstract

Chronic kidney disease is the main cause of mortality in patients with tuberous sclerosis complex (TSC) disease. The mechanisms underlying TSC cystic kidney disease remain unclear, with no available interventions to prevent cyst formation. Using targeted deletion of TSC1 in nephron progenitor cells, we showed that cysts in TSC1-null embryonic kidneys originate from injured proximal tubular cells with high mTOR complex 1 activity. Injection of rapamycin to pregnant mice inhibited the mTOR pathway and tubular cell proliferation in kidneys of TSC1-null offspring. Rapamycin also prevented renal cystogenesis and prolonged the life span of TSC newborns. Gene expression analysis of proximal tubule cells identified sets of genes and pathways that were modified secondary to TSC1 deletion and rescued by rapamycin administration during nephrogenesis. Inflammation with mononuclear infiltration was observed in the cystic areas of TSC1-null kidneys. Dexamethasone administration during pregnancy decreased cyst formation by not only inhibiting the inflammatory response, but also interfering with the mTORC1 pathway. These results reveal mechanisms of cystogenesis in TSC disease and suggest interventions before birth to ameliorate cystic disease in offspring.

Entities:  

Keywords:  Embryonic development; Mouse models; Nephrology

Mesh:

Substances:

Year:  2020        PMID: 32484794      PMCID: PMC7406292          DOI: 10.1172/jci.insight.136857

Source DB:  PubMed          Journal:  JCI Insight        ISSN: 2379-3708


  61 in total

1.  TSC1 activates TGF-β-Smad2/3 signaling in growth arrest and epithelial-to-mesenchymal transition.

Authors:  Antje Thien; Mirja Tamara Prentzell; Birgit Holzwarth; Kathrin Kläsener; Ineke Kuper; Christopher Boehlke; Annika G Sonntag; Stefanie Ruf; Lars Maerz; Roland Nitschke; Sushma-Nagaraja Grellscheid; Michael Reth; Gerd Walz; Ralf Baumeister; Elke Neumann-Haefelin; Kathrin Thedieck
Journal:  Dev Cell       Date:  2015-02-26       Impact factor: 12.270

2.  Tuberin Regulates Prostaglandin Receptor-Mediated Viability, via Rheb, in mTORC1-Hyperactive Cells.

Authors:  Chenggang Li; Xiaolei Liu; Yang Liu; Erik Zhang; Kantha Medepalli; Kouhei Masuda; Na Li; Kathryn A Wikenheiser-Brokamp; Andrew Osterburg; Michael T Borchers; Elizabeth J Kopras; David R Plas; Julia Sun; David N Franz; Jamie K Capal; Maxwell Mays; Yang Sun; David J Kwiatkowski; Anya Alayev; Marina K Holz; Darcy A Krueger; Brian J Siroky; Jane J Yu
Journal:  Mol Cancer Res       Date:  2017-07-14       Impact factor: 5.852

Review 3.  Renal disease in tuberous sclerosis complex: pathogenesis and therapy.

Authors:  Hilaire C Lam; Brian J Siroky; Elizabeth P Henske
Journal:  Nat Rev Nephrol       Date:  2018-11       Impact factor: 28.314

4.  Loss of FOXP3 and TSC1 Accelerates Prostate Cancer Progression through Synergistic Transcriptional and Posttranslational Regulation of c-MYC.

Authors:  Lianpin Wu; Baozhu Yi; Shi Wei; Dapeng Rao; Youhua He; Gurudatta Naik; Sejong Bae; Xiaoguang M Liu; Wei-Hsiung Yang; Guru Sonpavde; Runhua Liu; Lizhong Wang
Journal:  Cancer Res       Date:  2019-02-07       Impact factor: 12.701

5.  New insights into ADPKD molecular pathways using combination of SAGE and microarray technologies.

Authors:  Hervé Husson; Partha Manavalan; Viatcheslav R Akmaev; Ryan J Russo; Brian Cook; Brenda Richards; Dana Barberio; Dongyu Liu; Xiaohong Cao; Gregory M Landes; Clarence J Wang; Bruce L Roberts; Katherine W Klinger; Shelley A Grubman; Douglas M Jefferson; Oxana Ibraghimov-Beskrovnaya
Journal:  Genomics       Date:  2004-09       Impact factor: 5.736

6.  Dexamethasone represses signaling through the mammalian target of rapamycin in muscle cells by enhancing expression of REDD1.

Authors:  Hongmei Wang; Neil Kubica; Leif W Ellisen; Leonard S Jefferson; Scot R Kimball
Journal:  J Biol Chem       Date:  2006-10-30       Impact factor: 5.157

7.  Aptamer-targeted inhibition of mTOR in T cells enhances antitumor immunity.

Authors:  Alexey Berezhnoy; Iris Castro; Agata Levay; Thomas R Malek; Eli Gilboa
Journal:  J Clin Invest       Date:  2014-01       Impact factor: 14.808

Review 8.  Review of the Tuberous Sclerosis Renal Guidelines from the 2012 Consensus Conference: Current Data and Future Study.

Authors:  J Chris Kingswood; John J Bissler; Klemens Budde; John Hulbert; Lisa Guay-Woodford; Julian R Sampson; Matthias Sauter; Jane Cox; Uday Patel; Frances Elmslie; Chris Anderson; Bernard A Zonnenberg
Journal:  Nephron       Date:  2016-08-10       Impact factor: 2.847

9.  An estimation of the incidence of tuberous sclerosis complex in a nationwide retrospective cohort study (1997-2010).

Authors:  C-H Hong; H-P Tu; J-R Lin; C-H Lee
Journal:  Br J Dermatol       Date:  2016-04-17       Impact factor: 9.302

10.  Ex vivo analysis of renal proximal tubular cells.

Authors:  David Legouis; Aurélien Bataille; Alexandre Hertig; Sophie Vandermeersch; Noémie Simon; Eric Rondeau; Pierre Galichon
Journal:  BMC Cell Biol       Date:  2015-03-25       Impact factor: 4.241

View more
  1 in total

1.  Increasing mTORC1 Pathway Activity or Methionine Supplementation during Pregnancy Reverses the Negative Effect of Maternal Malnutrition on the Developing Kidney.

Authors:  Yaniv Makayes; Elad Resnick; Liad Hinden; Elina Aizenshtein; Tomer Shlomi; Raphael Kopan; Morris Nechama; Oded Volovelsky
Journal:  J Am Soc Nephrol       Date:  2021-05-06       Impact factor: 14.978

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.